Hanx Biopharma buys back 2,100 H-shares; treasury stock climbs to 246,000

Bulletin Express04-21 19:23

Hanx Biopharmaceuticals (Wuhan) Co., Ltd. disclosed that it repurchased 2,100 H-shares on 21 April 2026, according to its Next Day Disclosure Return filed with the Hong Kong Stock Exchange on the same date. The transaction was executed on the Exchange at prices ranging from HKD 31.26 to HKD 31.70, with a volume-weighted average of HKD 31.65 per share, for a total outlay of HKD 66,462.

The repurchase represents 0.0015% of the company’s outstanding shares (excluding treasury shares) prior to the transaction. Following the buyback, issued shares outstanding fell from 135.97 million to 135.97 million, while treasury shares increased from 243,900 to 246,000. Total issued share capital remained unchanged at 136.22 million shares.

The purchases were made under the share-repurchase mandate approved on 12 February 2026, which allows Hanx Biopharma to repurchase up to 13.62 million shares. Cumulative buybacks under this mandate now stand at 246,000 shares, equivalent to 0.18% of shares outstanding on the mandate approval date.

In line with Hong Kong listing rules, the company is subject to a 30-day moratorium on issuing new shares or disposing of treasury shares, ending on 21 May 2026.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1132596082?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-04-21 19:23","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1132596082","market":"us","top_or_hot":-1,"title":"Hanx Biopharma buys back 2,100 H-shares; treasury stock climbs to 246,000","media":"Bulletin Express","content":"<p>Hanx Biopharmaceuticals (Wuhan) Co., Ltd. disclosed that it repurchased 2,100 H-shares on 21 April 2026, according to its Next Day Disclosure Return filed with the Hong Kong Stock Exchange on the same date. The transaction was executed on the Exchange at prices ranging from HKD 31.26 to HKD 31.70, with a volume-weighted average of HKD 31.65 per share, for a total outlay of HKD 66,462.</p>\n<p>The repurchase represents 0.0015% of the company’s outstanding shares (excluding treasury shares) prior to the transaction. Following the buyback, issued shares outstanding fell from 135.97 million to 135.97 million, while treasury shares increased from 243,900 to 246,000. Total issued share capital remained unchanged at 136.22 million shares.</p>\n<p>The purchases were made under the share-repurchase mandate approved on 12 February 2026, which allows Hanx Biopharma to repurchase up to 13.62 million shares. Cumulative buybacks under this mandate now stand at 246,000 shares, equivalent to 0.18% of shares outstanding on the mandate approval date.</p>\n<p>In line with Hong Kong listing rules, the company is subject to a 30-day moratorium on issuing new shares or disposing of treasury shares, ending on 21 May 2026.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Hanx Biopharma buys back 2,100 H-shares; treasury stock climbs to 246,000</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHanx Biopharma buys back 2,100 H-shares; treasury stock climbs to 246,000\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-04-21 19:23</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Hanx Biopharmaceuticals (Wuhan) Co., Ltd. disclosed that it repurchased 2,100 H-shares on 21 April 2026, according to its Next Day Disclosure Return filed with the Hong Kong Stock Exchange on the same date. The transaction was executed on the Exchange at prices ranging from HKD 31.26 to HKD 31.70, with a volume-weighted average of HKD 31.65 per share, for a total outlay of HKD 66,462.</p>\n<p>The repurchase represents 0.0015% of the company’s outstanding shares (excluding treasury shares) prior to the transaction. Following the buyback, issued shares outstanding fell from 135.97 million to 135.97 million, while treasury shares increased from 243,900 to 246,000. Total issued share capital remained unchanged at 136.22 million shares.</p>\n<p>The purchases were made under the share-repurchase mandate approved on 12 February 2026, which allows Hanx Biopharma to repurchase up to 13.62 million shares. Cumulative buybacks under this mandate now stand at 246,000 shares, equivalent to 0.18% of shares outstanding on the mandate approval date.</p>\n<p>In line with Hong Kong listing rules, the company is subject to a 30-day moratorium on issuing new shares or disposing of treasury shares, ending on 21 May 2026.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"03378","symbol_name":"翰思艾泰-B","start_time":0,"source_url":"","article_id":"1132596082","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1132596082","pubTimestamp":1776770621,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Hanx Biopharmaceuticals (Wuhan) Co., Ltd. disclosed that it repurchased 2,100 H-shares on 21 April 2026, according to its Next Day Disclosure Return filed with the Hong Kong Stock Exchange on the...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"03378":"翰思艾泰-B"},"translate_title":"汉克斯生物制药回购2100股H股；库存股攀升至246,000股","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"03378":1},"content_text":"Hanx Biopharmaceuticals (Wuhan) Co., Ltd. disclosed that it repurchased 2,100 H-shares on 21 April 2026, according to its Next Day Disclosure Return filed with the Hong Kong Stock Exchange on the same date. The transaction was executed on the Exchange at prices ranging from HKD 31.26 to HKD 31.70, with a volume-weighted average of HKD 31.65 per share, for a total outlay of HKD 66,462.\nThe repurchase represents 0.0015% of the company’s outstanding shares (excluding treasury shares) prior to the transaction. Following the buyback, issued shares outstanding fell from 135.97 million to 135.97 million, while treasury shares increased from 243,900 to 246,000. Total issued share capital remained unchanged at 136.22 million shares.\nThe purchases were made under the share-repurchase mandate approved on 12 February 2026, which allows Hanx Biopharma to repurchase up to 13.62 million shares. Cumulative buybacks under this mandate now stand at 246,000 shares, equivalent to 0.18% of shares outstanding on the mandate approval date.\nIn line with Hong Kong listing rules, the company is subject to a 30-day moratorium on issuing new shares or disposing of treasury shares, ending on 21 May 2026.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"shareholding,SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1132596082","isCrawlerRequest":true}